CliffBio
small molecule

GAVRETO

PRALSETINIB

Loss of exclusivityJuly 2042latest FDA-listed patent expiry
CompanyRigel Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameGAVRETO
Active ingredientPRALSETINIB
Strength100MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2020
Marketing statusRX

Listed patents

PatentExpiresType
12448366July 2042substance
11273160April 2039use U-2952
12539303April 2039use U-2828
11872192April 2039use U-2952
11963958April 2039use U-2828
10030005November 2036substance, product

Regulatory exclusivity

CodeExpires
ODE-340December 2027
ODE-341December 2027
ODE-318September 2027

More from Rigel Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

GAVRETO patent cliff — loss of exclusivity July 2042 | CliffBio